RT @uptoTate: Long term RZB provides durable efficacy response in PsA through 100 weeks. No new safety signals. Abs 2145
Tweet Content
Long term RZB provides durable efficacy response in PsA through 100 weeks. No new safety signals. Abs 2145 #ACR22 @RheumNow https://t.co/HfJvS1HzDW https://t.co/T67lDnxeLy
Links
Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Re…
http://ow.ly/wvfu50LAllK
Show on Archive Page
On
Display in Search Results
On
PDQ
Off